The global protein A resins market is experiencing significant growth and is predicted to rise at a notable pace in the forthcoming years. Various Protein A resins are commercialized and have become a well-established platform for capturing monoclonal antibodies and Fc-fusion proteins. Monoclonal antibodies (mAbs) are proteins engineered to mimic or enhance the body's immune system. Protein A resins are the most frequently used affinity resins in biomanufacturing. Protein A chromatography is a very efficient purification procedure and is used as a capture step due to its specificity. Depending on the intended use for the target molecule (antibodies for diagnostic testing) Protein A capturing could be the sole chromatographic step required to achieve adequate product purity.
COVID-19 scenario analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
Top impacting factors: market scenario analysis, trends, drivers and impact analysis
Growing demand for Biotherapeutic products and the increasing pharmaceutical R&D spending are expected to drive the growth of this market during the forecast period. However, the availability of alternative purification methods and the high cost of resins are expected to limit the growth of this market. The interest of scientists and researchers in synthetic biology, and emphasis of the biopharmaceutical industry for use of protein-engineered products to develop protein-based drugs are some other key factors paving the growth of protein A resin market.
New product launches to flourish the market
Significant growth acceleration in the protein a-resins market was witnessed when GE Healthcare launched its MabSelect PrismA chromatography resin in 2017. Designed to purify bispecific antibodies (BsAbs) in a single step, protein a-chromatography has provided 90% purity levels. The resin makes effective usage of Protein-A ligand and a novel agarose bead to achieve dynamic binding capacities.
Key benefits of the report
- This study presents the analytical depiction of the global protein a resins market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the protein a resins market share.
- The current market is quantitatively analyzed to highlight the protein a resins market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed protein a resins market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions answered in the protein a resins market report
- Which are the leading players active in the protein a resins market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What are the projections for the future that would help in taking further strategic steps?
Protein A Resins Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Product |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Orochem, Bio-Rad Laboratories, Expedeon Ltd, Purolite Lifescience, Agarose Beads Technologies, Merck Millipore, Novasep, Abcam., Repligen Corporation, Genscript Corporation, GE Healthcare |
Loading Table Of Content...
